https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota
Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links An official website of the United States government Hereâ€™s how you know The .gov means itâ€™s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. U.S. Food and Drug Administration Search Menu Search FDA Submit search Featured Contact FDA FDA Guidance Documents Recalls, Market Withdrawals and Safety Alerts Press Announcements Warning Letters Advisory Committees En Español Products Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood, and Biologics Animal and Veterinary Cosmetics Tobacco Products Topics About FDA Combination Products Regulatory Information Safety Emergency Preparedness International Programs News and Events Training and Continuing Education Inspections and Compliance Science and Research Information For Consumers Patients Industry Health Professionals Federal, State and Local Officials In this section: Search for FDA Guidance Documents Search for FDA Guidance Documents Search General and Cross-Cutting Topics Guidance Documents Advisory Committee Guidance Documents Clinical Trials Guidance Documents Combination Products Guidance Documents Import and Export Guidance Documents Cross-cutting Guidance Documents Home Regulatory Information Search for FDA Guidance Documents Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies Search for FDA Guidance Documents GUIDANCE DOCUMENT Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies Guidance for Industry July 2013 Download the Final Guidance Document Read the Federal Register Notice Final Share Tweet Linkedin Email Print Docket Number: FDA-2013-D-0811 Issued by: Guidance Issuing Office Center for Biologics Evaluation and Research We, FDA, are informing members of the medical and scientific community, and other interestedÂ persons that we intend to exercise enforcement discretion regarding the investigational new drugÂ (IND) requirements for the use of fecal microbiota for transplantation (FMT) to treat ClostridiumÂ difficile (C. difficile) infection not responding to standard therapies. FDA intends to exercise thisÂ discretion provided that the treating physician obtains adequate informed consent from theÂ patient or his or her legally authorized representative for the use of FMT products. InformedÂ consent should include, at a minimum, a statement that the use of FMT products to treat C.difficile is investigational and a discussion of its potential risks. FDA intends to exercise thisÂ discretion on an interim basis while the agency develops appropriate policies for the study and use of FMT products under IND. Submit Comments Submit Comments Online You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5)) If unable to submit comments online, please mail written comments to: Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm 1061 Rockville, MD 20852 All written comments should be identified with this document's docket number: FDA-2013-D-0811. Questions? Content current as of: 09/10/2019 Regulated Product(s) Biologics Vaccines Search for FDA Guidance Documents Search for FDA Guidance Documents Search General and Cross-Cutting Topics Guidance Documents Advisory Committee Guidance Documents Clinical Trials Guidance Documents Combination Products Guidance Documents Import and Export Guidance Documents Cross-cutting Guidance Documents Footer Links FDA Archive About FDA Accessibility Visitor Information Website Policies / Privacy No FEAR Act FOIA HHS.gov USA.gov Contact FDA Follow FDA on Facebook Follow FDA on Twitter View FDA videos on YouTube Subscribe to FDA RSS feeds FDA Homepage Contact Number 1-888-INFO-FDA (1-888-463-6332) Back to Top
